BioAtla (NASDAQ: BCAB)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of BioAtla (NASDAQ: BCAB) through any online brokerage.
There are no as such competitors for BioAtla.
The latest price target for BioAtla (NASDAQ: BCAB) was reported by Credit Suisse on Thursday, May 5, 2022. The analyst firm set a price target for 5.00 expecting BCAB to rise to within 12 months (a possible 116.45% upside). 3 analyst firms have reported ratings in the last year.
The stock price for BioAtla (NASDAQ: BCAB) is $2.31 last updated May 20, 2022, 8:00 PM UTC.
There are no upcoming dividends for BioAtla.
BioAtla’s Q2 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for BioAtla.
BioAtla is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.